Objective: The study aimed to evaluate the impact of the COVID-19 pandemic on levels of anxiety and depressive symptoms in children and adolescents. Design: Cross-sectional surveys were carried out on the mental health of children; one survey was conducted before the COVID-19 pandemic and one into the pandemic, 15 months after the school closures and implementation of lockdown and social distancing. Demographic data and COVID-19 pandemic-related data were collected from specific parent-report and self-report questionnaires. Participants: Participants included children and adolescents between ages 6 and 16 years, attending a tertiary care hospital without any diagnosed major psychiatric or chronic disorder. Analysis: Data were collected at two points (before the COVID-19 pandemic and during it) and compared. Levels of anxiety and depressive symptoms were compared and tested for statistically significant differences between these two points using appropriate statistical tests. Regression models were constructed to predict the factors affecting increased anxiety levels and depressive symptoms in the COVID-19 period. Results: 832 and 1255 children/adolescents were included in the study during the pre-COVID-19 and COVID-19 times, respectively. The median age of the participants was 10 years (IQR=4 years). The median (IQR) Spence Children’s Anxiety Scale score was 24 (12) at the pre-COVID-19 point and 31 (13) during the COVID-19 pandemic (p<0.001, r=−0.27). 11% and 16% of children reported being depressed at these two-time points, respectively (p=0.004, φ c =−0.063). Regression analysis showed that many factors, including the duration of smartphone use, female gender and only child status, were associated with increased anxiety or depression levels. Conclusion: A large proportion of children had elevated anxiety and depressive symptoms during the pandemic relative to before the pandemic, suggesting a need for measures to engage children in healthy habits to protect children’s mental health and continuous monitoring of children during such scenarios.
20 February 2025 in Exploration of Targeted Anti-tumor Therapy
Background: Breast cancer is a leading cause of mortality in women. Hormone therapy plays a crucial role in treatment of hormone receptor-positive metastatic breast cancer. Elacestrant is a selective estrogen receptor degrader (SERD) that has shown promise in early-phase clinical trials. This post-hoc analysis systematically evaluates elacestrant’s effectiveness in hormone receptor-positive metastatic breast cancer patients, providing insights into its efficacy, safety, and potential advantages over existing treatments. Methods: We adhered to the PRISMA Statement 2020 guidelines and systematically searched the databases PubMed/MEDLINE, ClinicalTrials.gov, Web of Science, and Embase. We conducted the post-hoc analysis using R software (V 4.3.3), applying the inverse variance method and the DerSimonian-Laird estimator to pool effect estimates with a random-effects model. We assessed heterogeneity using the Cochran’s Q test and the I2 statistic. Results: Our post-hoc analysis encompassed 3 clinical trials and a total of 835 participants. The mean age of all 835 participants across the three trials was 59.5 years (95% CI: 58.7–60.3). The pooled progression-free survival (PFS)—was estimated at 4.38 (95% CI: 7.58–16.34, P = 0.47), and the pooled objective response rate (ORR) was 7% (95% CI: 3–18%, P = 0.04), with significant heterogeneity observed among the studies. Discussion: Elacestrant shows promise for improving outcomes in hormone receptor-positive metastatic breast cancer, but further research is needed to confirm its effectiveness. Future studies should include larger sample sizes, comprehensive phase II and III trials, and investigation of elacestrant in combination with other drugs or in preoperative settings.
Background: Renal cell carcinoma accounts for nearly 15,000 deaths annually in the US, and approximately 30–40% of patients present with metastatic disease (mRCC). The advent of immune checkpoint inhibitors (IO) and tyrosine kinase inhibitors (TKI) has revolutionized the treatment paradigm of patients with mRCC. However, the role of cytoreductive nephrectomy (CN) in the IO-TKI era, particularly for rare and understudied histologies such as non-clear-cell RCC, remains poorly understood. Methods: We conducted a retrospective cohort study of patients with metastatic non-clear-cell RCC. Patients were stratified by receipt of CN. Baseline demographic, clinical, histologic, and metastatic site variables were collected. Overall survival was analyzed using Kaplan–Meier methods and compared with the log-rank test. Cox proportional hazards regression was performed to identify independent predictors of survival, including CN, systemic therapy, year of diagnosis, histology, and metastatic sites. Results: Among 2753 patients with metastatic nccRCC, 1654 (60.1%) underwent CN and 1099 (39.9%) did not undergo CN. The 2-year and 5-year OS rates were 35.52% and 19.22% in the CN group versus 18.53% and 7.47% in the non-CN group (p < 0.001). In the doubly robust IPTW-weighted multivariable Cox regression analysis, CN was associated with improved overall survival, corresponding to a 40% lower risk of death compared with no CN (HR 0.60, 95% CI 0.54–0.66; p < 0.001). Additionally, more recent treatment eras were associated with progressively improved overall survival, with patients diagnosed between 2015 and 2017 and 2018 onward demonstrating significantly improved OS compared with those diagnosed between 2004 and 2014. Conclusions: Our study demonstrates that CN was associated with improved OS in patients with non-clear-cell mRCC by reducing the risk of death by 40% after adjusting for baseline characteristics. These findings emphasize the role of CN even in the IO-TKI era for the management of patients with non-clear-cell mRCC. However, these findings should be interpreted in the context of the retrospective study design, potential selection bias, and lack of granular systemic therapy data within the NCDB.
1 April 2025 in Journal of Adolescent and Young Adult Oncology
Background: Cancer incidence (CI) and mortality vary significantly among countries and are impacted by numerous factors including the country’s income and human development index (HDI). Cancer mortality (CM) in the adolescent and young adult (AYA) population, the age group of 15 − 39 years, has seen minimal improvement over the past few decades. Our study aims to identify disparities in this group and analyze the influence of income and HDI on these outcomes. Methods: We utilized the GLOBOCAN database estimates of incidence and mortality for year 2022 in 185 countries or territories for 36 cancer types to analyze the trends in crude rate of CI and crude rate of CM. Results: Globally, in 2022, an estimated 1.32 million new cases of cancer and 379,273 deaths were reported among individuals aged 15–39 years. The CM-to-CI ratios for countries with very high, high, medium, and low HDI were 16.6, 1:4.4, 1: 2.2, and 1:1.9, respectively. Similarly, based on the income level of countries, the CM-to-CI ratios were observed to be 1:8.6 for high-income, 1:4.8 for upper-middle-income, 1:2.3 for lower-middle-income, and 1:1.7 for low-income nations. Conclusion: Countries with a higher HDI and income levels experienced a notably higher incidence of cancer. However, the mortality rates were inversely related to the income and HDI. Mortality-to-incidence (CM:CI) ratios were alarmingly higher in countries with lower income and lower HDI. Introducing age-specific reforms and programs for the understudied AYA population in low to middle-income countries can have a significant impact on reducing CM globally.
10 April 2023 in International Journal of Geriatrics and Gerontology
Cognitive dysfunction disorders, such as Alzheimer’s disease and other forms of dementia, are prevalent among the geriatric population. The management of cognitive dysfunction disorders requires a multidisciplinary approach that includes pharmacological and non-pharmacological interventions. This article provides an overview of recent management approaches for geriatric populations suffering from cognitive dysfunction disorders. Pharmacological management includes the use of cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists to improve cognitive function and delay disease progression. Non-pharmacological management includes cognitive stimulation therapy, physical activity, and social engagement to improve cognitive function and maintain quality of life. Occupational therapy and speech therapy can address functional impairments and communication difficulties associated with cognitive dysfunction disorders. Clinical trials to evaluate the effect and the safety of caregiver support can also play a significant role in laying down new strategies. Emerging therapies, such as immunotherapy, gene therapy, and stem cell therapy, hold promise for disease modification and prevention. However, these therapies are still in the early stages of development and require further research and. Overall, the management of cognitive dysfunction disorders in geriatric populations requires a personalized approach that considers the individual needs and preferences of each individual. Collaborative care models that involve patients, caregivers, and healthcare providers can promote effective disease management and improve patient outcomes. Future research should focus on identifying new therapeutic targets and interventions to prevent and treat cognitive dysfunction disorders in geriatric populations.
Background: Splenic marginal zone lymphoma (SMZL) is a rare indolent lymphoma with extremely limited population-level evidence on social and treatment correlates of survival. Methods: We conducted a retrospective cohort study using SEER (2000 to 2022) to evaluate OS in primary SMZL (ICD O 3 9689; spleen C42.2). We summarized baseline features and treatments and used Kaplan–Meier and Cox regression. Results: The cohort included 3548 patients (mean age: 68.2 years; 53.6% female). Most were White (89.8%) and non-Hispanic (92.1%). The Ann Arbor stage was missing in 39.4%. Treatment included systemic antineoplastic therapy in 26.4%, beam radiation in 0.7%, and primary site surgery in 21.4%. At last follow-up, 56.8% were alive; non-Hodgkin lymphoma accounted for 15.8% deaths in the cohort, with substantial competing causes including heart disease (6.1%). In multivariable Cox analysis, OS was independently associated with age (HR 1.082 per year, 95% CI 1.072–1.091), male sex (HR 1.34, 95% CI 1.14–1.57), Hispanic ethnicity (HR 1.42, 95% CI 1.08–1.88), systemic antineoplastic therapy (HR 1.42, 95% CI 1.18–1.70), divorced/separated marital status vs. married (HR 1.35, 95% CI 1.03–1.77), and stage IV disease (HR 1.70, 95% CI 1.16–2.50). Race and year of diagnosis were not independently associated with OS in the adjusted model. Conclusions: In our large population-based analysis, OS in SMZL tracks with demographic and social variables and competing risks. Stage missingness and treatment selection limit causal inference for management effects.